ProfileGDS5678 / 1426476_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 96% 96% 95% 95% 96% 96% 96% 95% 96% 96% 96% 95% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.5771695
GSM967853U87-EV human glioblastoma xenograft - Control 28.7516596
GSM967854U87-EV human glioblastoma xenograft - Control 38.7917696
GSM967855U87-EV human glioblastoma xenograft - Control 48.701195
GSM967856U87-EV human glioblastoma xenograft - Control 58.5386595
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.700396
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.4515596
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.6182696
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.4957495
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.6709396
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.8183996
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.764996
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.6294195
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.7310196